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Background: Medication-taking behavior, specifically non-adherence, is significantly associated with treatment
outcome and is a major cause of relapse in the treatment of psychotic disorders. Non-adherence can be
multifactorial; however, the rates and associated risk factors in an Ethiopian population have not yet been
elucidated. The principal aim of this study was to evaluate adherence rates to antipsychotic medications, and
secondarily to identify potential factors associated with non-adherence, among psychotic patients at tertiary care
teaching hospital in Southwest Ethiopia.
Methods: A cross-sectional study was conducted over a 2-month period in 2009 (January 15th to March 20th) at the
Jimma University Specialized Hospital. Adherence was computed using both a compliant fill rate method and
self-reporting via a structured patient interview (focusing on how often regular medication doses were missed
altogether, and whether they missed taking their doses on time). Data were analyzed using SPSS for windows
version 16.0, and chi-square and Pearsons r tests were used to determine the statistical significance of the
association of variables with adherence.
Result: Three hundred thirty six patients were included in the study. A total of 75.6% were diagnosed with
schizophrenia, while the others were diagnosed with other psychotic disorders. Most (88.1%) patients were taking
only antipsychotics, while the remainder took more than one medication. Based upon the compliant fill rate, 57.5%
of prescription fills were considered compliant, but only 19.6% of participants had compliant fills for all of their
prescriptions. In contrast, on the basis of patients self-report, 52.1% of patients reported that they had never missed
a medication dose, 32.0% sometimes missed their daily doses, 22.0% only missed taking their dose at the specific
scheduled time, and 5.9% missed both taking their dose at the specific scheduled time and sometimes missed their
daily doses. The most common reasons provided for missing medication doses were: forgetfulness (36.2%); being
busy (21.0%); and a lack of sufficient information about the medication (10.0%). Pill burden, medication side-effects,
social drug use, and duration of maintenance therapy each had a statistically significant association with medication
adherence (P≤ 0.05).
Conclusion: The observed rate of antipsychotic medication adherence in this study was low, and depending upon
the definition used to determine adherence, it is either consistent or low compared to previous reports, which
highlights its pervasive and problematic nature. Adherence must therefore be considered when planning treatment
strategies with antipsychotic medications, particularly in countries such as Ethiopia.
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Medication adherence relates to a patient’s medication-
taking behavior, and specifically refers to the extent to
which a patient follows the mutually agreed treatment
plan. Non-adherence to medication is known to be asso-
ciated with poorer treatment outcomes, particularly in
the management of chronic disease, yet numerous clin-
ical studies have reported an average adherence rate of
only 43.1% to 78.0% among patients receiving treatment
for various conditions.
In the treatment and management of psychotic disor-
ders, non-adherence to medication is particularly prob-
lematic. Antipsychotic medications are effective in
treating psychiatric problems, including schizophrenia;
however, the maximum benefit that a patient derives
from these medications is highly dependent on their ad-
herence to treatment [1]. The favorable rates of relapse
prevention reported in controlled trials cannot usually
be applied to everyday practice, due to poorer adherence
in the ‘real world’ setting; as highlighted by Cramer and
Rosenheck [2], outside of clinical trial settings, the aver-
age rate of adherence to antipsychotic regimens is only
58%.
Although non-adherence is a ubiquitous problem in
medicine [3], the nature of schizophrenia and other
psychotic disorders makes it especially difficult for
patients to adhere to treatment [4]. First, schizophrenia
is an illness in which insight into the condition, and
therefore need for treatment, is more likely to be
impaired compared to other illnesses [5]; this lack of
insight has been shown to be associated with non-
adherence to medications [6-8] and other psychosocial
treatment [9]. Second, disorganization and cognitive im-
pairment are additional symptoms of schizophrenia that
interfere with medication management [10-12], particu-
larly over the long-term given the chronic nature of the
illness. In general, the more prolonged the medication
treatment period, the lower the rates of adherence, and
this has been reported in other chronic diseases [13].
Furthermore, the greater the exposure to treatment the
more likely the patient is to experience side-effects, in-
creasing the patient’s reluctance to adhere to treatment;
unfortunately, the advent of atypical antipsychotics has
not significantly reduced the potential for adverse drug
events [14,15]. Finally, schizophrenia and its treatment
(antipsychotics) are subject to stigma [16].
The impact of medication non-adherence on clinical
outcomes in the treatment of schizophrenia is signifi-
cant, as studies have shown that deviation from main-
tenance antipsychotic treatment leads to disease relapse,
increased clinic and emergency room visits, and re-
hospitalization [17,18]. Furthermore, mortality in per-
sons with schizophrenia is two to four times greater than
that in the general population [19,20], which is in partdue to the out-right increased risk of suicide, but also to
non-adherence to treatment for both the psychosis as
well as other underlying physical illnesses [21]. Subse-
quently, this compromises the individual’s quality of life
and function, and increases the economic burden to the
health-system [22].
In Ethiopia, due to the under-resourced health-care
system, medication non-adherence rates are potentially
much higher, thereby contributing to a substantial wor-
sening of disease, increased mortality, and increased
health care costs [4]. Given the significance of this as a
health issue and the scarcity of data to inform the scope
of this problem in the local setting, the primary aim of
this study was to evaluate adherence rates to anti-
psychotic medications, and secondarily to identify pos-
sible reasons for non-adherence to medications, among
patients with psychosis in Jimma University Specialized
Hospital in Southwest Ethiopia.Methods
Study design
A cross-sectional study was conducted over a 2-month
period in 2009 (January 15th to March 20th), on the in-
ternal medicine ward of the Jimma University Specia-
lized Hospital (JUSH), which is the only referral hospital
in the Oromia Regional State of South West Ethiopia.
The adherence rate to anti-psychotic medications and
identification of possible reasons for non- adherence was
evaluated using patients self-reporting and pharmacy re-
fill record. JUSH has four major in-patient wards: in-
ternal medicine (where psychiatric patients receive their
treatment), surgery, pediatrics, and gynecology and
obstetrics, and additionally provides ambulance/emer-
gency services, pharmacy, outpatient services, blood
bank, and diagnostics (e.g., laboratory, X-ray, ultrasound
scanner, electrocardiogram).Patient selection
Since psychiatric patients receive their treatment in the in-
ternal medicine ward of the hospital, patients of the in-
ternal medicine ward were eligible for inclusion. All
patients who were prescribed antipsychotics within a 3-
month time period were identified and consecutive
patients meeting selection criteria were approached about
inclusion in the study. The sample was restricted to
patients with a diagnosis of schizophrenia, schizoaffective
disorder, mood disorder with psychotic features, or psych-
osis not otherwise specified. Patients must have received
maintenance therapy for at least 3 months to be included
in the study. Excluded were patients who were taking
anti-psychotic medication for non-psychotic mood disor-
ders (e.g. disorders or behavioral disorders secondary to
other diseases), patients who had started antipsychotic
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the age of 10.Data collection
Adherence to prescribed medication regimens was deter-
mined with a quantitative, structured questionnaire. Face
and content validity of the questionnaires were assessed
through in-depth discussion with three experienced fac-
ulty colleagues and five senior internists in the internal
medicine department at the study site. In addition, the
questionnaires were pre-tested to minimize ambiguity
and ensure the completeness of data capture. The result
of the pretest was not included in the final analysis.
Patients who were refilling a prescription were inter-
viewed with the developed questionnaire. Using this
questionnaire, a patient who reported that they had
never missed either a daily dose or the time of taking a
dose was considered to be adherent.
Medication adherence was also assessed by the com-
pliant fill rate (CFR) method [23]. CFR represents the
proportion of total fills that are adherent, i.e., filled at
time-appropriate intervals over a specified time period.
Adherence was assessed by comparing the number of
days of medication supply with the number of calendar
days between fills. A prescription fill was considered ad-
herent if it took place before the completion of the pre-
vious prescription and there was no more than 20% of
the medication still with the patient [23,24]. For ex-
ample, if a patient received 60 tablets on a prescription
and was instructed to take one tablet a day, the fill
would be considered adherent if the patient collected
the subsequent prescription within 48–60 days of the
previous one. An exception was when a prescription be-
came invalid because of a change in therapy. In such
cases, the medication was either prematurely or delayed
in being filled, but the fill was considered adherent.
Medication profiles were also examined to calculate
the number of scheduled oral daily medications and the
total number of prescribed tablets or capsules prescribed
per day. If a patient was prescribed more than one agent
for a disorder, adherence rates for all medications were
calculated and the agent with the highest non-adherence
was recorded and used for data analysis.Sample size
Since there have been no previous study of medication
adherence in Ethiopia, a prevalence rate (p) of 50%, con-
fidence interval of 95% and margin of error (d) of 5%
were used for sample size calculation. The sample size
was calculated using the [Z2 *p* (1-p)]/d2 formula, where
Z is the standard normal confidence internal (1.96). Ac-
cordingly, the appropriate sample size was calculated as
384.Data analysis
Data were coded, checked for completeness and
consistency, and analyzed using SPSS Version 16.0. De-
scriptive statistics were used to determine patient demo-
graphics, medication information, and adherence rates.
The association between variables was calculated with
Chi-square test of association and Pearsons r test where
appropriate.
Ethics
The proposal was reviewed and approved by the ethical
clearance committee of Jimma University. The aims of
the study were provided to potential participants and
informed consent was obtained prior to inclusion in the
study.
Results
Socio demographic characteristics of patients
Among three hundred and eighty four participants who
were approached regarding the study, 336 were included,
resulting in a response rate of 87.5%. Of the remainder,
48 either did not fulfill the inclusion criteria, or
give written consent for inclusion in the study. The co-
hort was comprised of 54.8% males with a mean age of
35 +/− 11.9 years. The majority of the study subjects
were Orthodox Christian by religion and 26.5% were un-
employed (Table 1).
Clinical characteristics of the patient
Amongst study participants, 75.6% were diagnosed with
schizophrenia, 9.2% with schizoaffective disorder while
the rest as mood disorder with psychotic features
(11.9%) and psychosis not otherwise specified (3.3%).
Most of the participants were taking only antipsychotics
(88.1%), while 6.8% were taking antipsychotics and anti-
depressant, 3.9% antipsychotics and mood stabilizers and
1.2% a combination of antipsychotics, antidepressant
and mood stabilizers. Participants attended for a medical
checkup and prescription refill at 2 monthly intervals,
during which time the pill counts, structured question-
naires and CFR analysis took place.
In relation to pill burden (in terms of the overall num-
ber of medications prescribed), the majority (74.0%) of
patients were prescribed only one agent, 24.7% were tak-
ing two agents, and 1.4% were using three agents; the
vast majority (96%) of doses were prescribed as once-
daily dosing regimens.
In relation to the patients’ experiences of side-effects
with their medications, 44.1% reported ongoing depres-
sion, 14.7% experienced weight gain, 8.8% had extra-
pyramidal side-effects; nearly a quarter (23.5%) of patients
reported experiencing multiple side-effects. Among those
patients who experienced side-effects, when asked about
what measures they had taken to avoid the side-effects,
Table 1 Socio demographic characteristics of study
participants
S.No. Socio-demographic Characteristics Frequency Percent
1 Gender Male 185 54.8
Female 151 45.5









4 Living Condition With family 300 89.9
Living alone 19 5.5
Others 17 4.5
5 Educational status Diploma &above 62 18.3
10-12 grade 117 34.7
7-10 grade 71 21
1-6 grade 33 9.6
No formal schooling 53 13.2
6 Occupational status Unemployed 89 26.5






7 Religion Orthodox 145 42.9
Muslim 83 24.7












Lack of information 17 10.5
Being busy 34 21.0
Decision to omit 20 12.4
Others 27 12.4
Both forgetfulness and being busy 7 3.8
Total 164 100.0
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stopped taking their doses, 4.6% informed their health
professional/s, 4.1% told their family members, and 0.5%
stopped going to work. Most (95.9%) of patients
responded that they felt comfortable in openly discussing
their medication issues with their health professional/s
(e.g., pharmacists, doctors, nurses and others).
Most patients (72.6%) reported that they had no previ-
ous exposure to any social/ recreational drugs. Amongthose who had been exposed to these agents, khat
(n = 83), cigarette (n = 28), and alcohol (n = 20), were
most commonly reported by the patients. Among social/
recreational drug users, 34% reported feeling depressed,
13.2% felt that their illness had worsened, and 18.9%
reported feeling ‘different’ when they stopped using so-
cial/ recreational drugs.
Adherence rate and factors associated with non-
adherence
Adherence to antipsychotic medications was measured
when patients presented for prescription (medication)
refills and medical check-ups (outpatient clinic visits)
every two months.
Patient’s self-reported adherence to medication
Approximately half (52.1%) of patients stated that they
had never missed taking their prescribed medication,
which included neither missing the daily dose outright
nor missing the instructed time of dose administration.
A small proportion (5.9%) of patients reported that they
sometimes missed taking their medications in relation to
either taking the daily dose outright and/or missing the
instructed time of dose administration. Among those
who reported that they had missed taking their medica-
tion, the most common reason (36.2%) for not taking
doses was forgetfulness (Table 2).
Compliant fill rate (CFR)
Based upon the compliant fill rate, 57.5% of prescription
fills were considered compliant. Of the subjects with 100%
CFR (n= 66, 19.6%), the number of females (n= 35, 23.2%
of all females) was greater than the number of males
(n= 31, 16.8%). Accordingly, at CFR of 25% (n= 98), CFR
50% (n= 99) and CFR 75% (n= 68), the number of male
patients was slightly greater. When CFR was analyzed by
marital status, 86 of 150 never married participants
(57.3%) had a CFR <50%, whereas among the 137 married
patients, 86 (62.9%) had a CFR< 50%. Distribution of
rate of adherence by education status indicated that
among the 66 patients with CFR= 100%, the majority
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number of patients with educational status of diploma and
above who had 100% CFR was 9.8%, compared to 9 of 45
(20%) who did not have any formal schooling. Conversely
among the 61 patients who had an educational status of
diploma and above, a large proportion (n= 46, 75.4%) had
a CFR< 50% (Table 3).
Amongst social drug users, 80, 72.2 and 76.9% respect-
ively had CFR< 50% (P = 0.05 for the comparison of all
social drug users vs non-social drug users). When the
number of medications taken was compared with the
rate of adherence, it was found that, amongst patients
with high adherence (n = 66, CFR = 100%), 53.5% were
taking one medication and 44.2% were taking two medi-
cations. Furthermore, amongst patients with CFR= 75%
(n = 68), 84.1% were taking just one medication. The
number of medications and rate of adherence was sig-
nificantly associated - as the number of medication
increased, the patients’ adherence decreased (r =−0.12,
p = 0.01).
One hundred eighty four patients (54.8%) took medi-
cations for more than a year and 152 for less than one
year. When the rate of adherence was compared with
the duration of antipsychotic drug use, it was found that
those patients with a duration of maintenance therapy
greater than a year had better adherence rate (r = 0.54,
p = 0.04, Table 4).
Based on the association of different variables and rate
of adherence, there was no statistically significant associ-
ation between age, sex, regime, income, educational, and
occupational status of the patients (P> 0.05), but the
duration of antipsychotic medication use, experiencing a
side effect of medications, exposure to social drugs and
the total number of medications currently taken did
show a significant association with rate of adherence
(Table 4).
Discussion
Methods of assessing medication adherence
Medication adherence describes the extent to which the
patient continues the agreed treatment or intervention
as prescribed. In other words, adherence can be defined
as the degree of conformity between treatment behavior
and treatment standard [4]. Understanding adherence
to pharmacotherapies is crucial in clinical practice to
ensure optimal clinical outcomes. There is no single
measure accepted as the “gold standard” for assessing
adherence, as each of the commonly employed methods
have distinct advantages and disadvantages [25-27].
Frequently used methods of assessing participant ad-
herence to pharmacological interventions include self-
report measures: participant interviews, questionnaires,
and diaries [27-31]. These methods are simple and inex-
pensive, but they are limited as they are subjective, crudeand relatively inaccurate [25,32]. Although some suggest
that patient-recall and refill history assessments are ac-
curate enough (especially if they are performed in com-
bination with other methods [33,34]), it is generally
accepted that they substantially overestimate medication
adherence [29,35]. Additionally, the ability of patient re-
call and refill history to detect changes in adherence is
unknown [32].
Pill counts are inexpensive and are frequently utilized;
whilst they provide information about the number of pills
taken, it is difficult to determine actual medication con-
sumption, as they rely upon the assumption that medica-
tions missing from the pill bottle were taken [36], and
patients can intentionally or unintentionally manipulate
this measure [25]. In addition, pill counts are laborious
and rely upon accurate reporting dates for starting pre-
scriptions. However, it has shown that pill counts can be
more precise when carefully performed [25,32], and they
can show both differences in patient adherence to therapy
and reported the rate of adherence (from which we can
detect non-adherence), in addition to measuring the
changes in adherence across time [32]. Pill counts are
regarded as being the most common way to assess adher-
ence [37]. They are more accurate than self-report or refill
history [38], but are tedious and difficult to administer
[32]. Other measures such as electronic bottle caps are
sophisticated and may be more accurate, but are costly
[20], whilst biological methods (eg urine analysis and bio-
markers) are precise measures of ingestion, but are not al-
ways available and practical [37].
Medication adherence and factors associated with non-
adherence
This study revealed that adherence to antipsychotic
medications was low in our study population. Previously
reported rates of adherence for anti-psychotic medica-
tions ranged from 25% to 75% [14,39-41], which is com-
parable to the reported adherence rate in this study,
which showed that patients reported taking medications
as prescribed and filled their medications at appropriate
intervals just over half of the time. However, if we con-
sider 100% CFR to represent the true rate of adherence,
fewer than 20% of patients would have been considered
adherent throughout the study period, which is quite
low compared to these previous reports.
Given the consequences of antipsychotic discontinu-
ation and haphazard antipsychotic use, the poor adher-
ence rates demonstrated in this and other studies are
troubling. Previous studies have reported that patients
who discontinue antipsychotics may be two to five times
more likely to relapse as other patients, leading to un-
necessary suffering [22,42]. Robinson and colleagues [42]
reported that 82% of first-episode patients experienced
at least one relapse within 5 years of follow-up, and that
Table 3 Number of adherence of patients defined by socio- demographic characteristics
Socio-demographic
Characteristic
Description Compliant Fill Rate (CFR)
25% 50% 75% 100%
Gender Male 61 57 35 31
Female 37 48 32 35
Age (in years) 10-20 20 12 12 12
21-30 26 37 22 25
31-40 20 25 12 17
41-50 11 6 6 6
Marital status Never married 38 48 29 35
Married 38 48 28 23
Divorced 11 3 3 3
Widowed 6 3 6 5
Educational status Diploma &above 23 23 9 6
10-12 grade 28 37 29 23
7-10 grade 23 18 14 15
1-6 grade 6 11 3 12
No formal schooling 17 11 8 9
Occupational status Unemployed 20 291 12 28
Private NGO 12 17 12 11
Government 26 20 12 5
Farmer 18 8 8 5
Student 11 6 6 5
Merchant 5 9 3 2
Others 5 15 12 12
Religion Orthodox 46 43 29 26
Muslim 20 26 14 20
Protestant 23 28 18 15
Catholic 6 3 2 2
Others 3 5 5 3
Monthly income (In Ethiopian Birr) >300 18 22 15 15
200-300 23 20 14 11
100-200 26 22 14 9
< 100 22 28 18 17
9 12 6 14
Table 4 Association between rate of adherence and
different variables
Variables P- value Pearson correlation
coefficient (r)
Duration of medication 0.04 0.54
Side effect of medications 0.03 −0.19
Exposure to social drugs 0.05 −0.13
Number of different types of medication 0.01 −0.12
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more likely to relapse. It might be speculated that after
experiencing one relapse, patients would be substantially
less likely to discontinue medication, so our study is par-
ticularly noteworthy in suggesting factors that might
contribute to non-adherence.
In our study over the half of patients reported that
they had never missed either a daily dose or the time of
taking a dose, and while over half of all prescriptions
were filled in an adherent manner, only 19.6% of the
study population was 100% adherent according to the
CFR method. This demonstrates the fundamental
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method to measure medication adherence. Patients’ self-
report may still represent an under-reporting of the
magnitude of the problem [43], whereas methods such
as CFR are less prone to manipulation, and may offer a
better approximation of the true adherence status.
Whilst there was no association between adherence
rates and age, gender, income, religion and educational
status of the patients, we did find an association between
the rate of adherence and duration of maintenance ther-
apy. This is supported by some [14], but not other stud-
ies [11,43,44]. In a naturalistic sample, younger age is
likely to be associated with a shorter duration of illness,
which we observed to be associated with a lower rate of
adherence. Two mechanisms may underlie this observa-
tion. The first involves patients early in the course of
their illness being more willing to take risks to find out
if they could remain well without medication, especially
before they encounter repeated episodes of relapse. The
second relates to a potential selection bias of our out-
patient population, where patients with longer illness
duration who attend clinic regularly are more likely to
be compliant with their treatment. In our study, over
half of our patients had received maintenance therapy
for more than one year, and these patients had the high-
est rates of adherence. Investigators examining the
course of schizophrenia have observed that positive
symptoms show a modest improvement over time
[45,46], and it may be that adherence improves along
with the decline in these severe psychotic symptoms.
As with other studies [2,8,14], these results have
shown an association between the quantity of medica-
tions taken and the adherence rate. This may be due to
an association between an increasing number of medica-
tions with misunderstanding that may arise as a result of
complex regimen and/or confusion of instructions from
health professionals and health care givers.
Individuals noted to use social drugs (chat, cigarette,
alcohol) were significantly less likely to be adherent to
their antipsychotic medication. This finding is consistent
with previous researches [45-50], and can be explained
by the fact that social drugs themselves are a risk factor
for several psychiatric manifestations. Similar research
showed that active substance abuse has been found to
have a nearly eight-fold higher risk of non-adherence
[8]. These abusive substances may have an effect on the
cognitive abilities of patients [51], which in turn may
affect adherence.
Kozuki and Froelicher [51] demonstrated that comor-
bid situations may adversely affect medication adherence
and prognosis. Since over three quarters of the partici-
pants in our study did not have additional medical ill-
ness, this was not assessed in this study, as the numbers
were too small to draw accurate conclusions. Also, theeffect of the type of antipsychotic medication (typical
versus atypical) on the adherence rate was not assessed,
as atypical agents were not available at the hospital dur-
ing the study period.
In the present study, communication between the
patients and the health professional was excellent, as over
95% responded that they felt comfortable in openly dis-
cussing their medication issues with their health profes-
sional/s. This clarity of communication is very supportive
in overcoming a significant barrier to adherence, because
when misunderstanding occurs, treatment becomes more
complex and side effects are not managed.
Knowledge of side effects, dosage regimen and the
name of their medications had an effect on adherence in
this study, which replicates previous results [9,14]. Simi-
lar to other studies [1,16], we have shown that confusion
and forgetfulness are the major obstacles in achieving
adherence to a medication regimen.Limitation
The findings of this study should be interpreted with
some acknowledgement of the limitations. Being a cross-
sectional design conducted at a single university Hos-
pital, the study findings might be non-representative of
the broader patient population, particularly in view of
the response rate. The self-report method used in this
study to measure treatment adherence might substan-
tially overestimate medication adherence, as it relies on
patient recall. Furthermore, this approach might not
fully identify all of the factors contributing to non-
adherence, nor accurately measure incidence, or associa-
tions. Despite the above limitations, the study identifies
issues for further in-depth investigation regarding medi-
cation adherence in psychosis in Ethiopia.Conclusion
Adherence to antipsychotic medications is relatively low.
Pill burden, exposure to social/recreational drugs, and
experiencing side-effects from medication may decrease
adherence to treatment. Prescribers need to more closely
focus on implementing treatment plans that patients
understand and to which they agree and commit. The
pharmacist should provide appropriate counseling on
medications, emphasizing the importance of adherence,
to both patients and their careers.
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